Rocket Pharmaceuticals (RCKT) presented its cardiomyopathy pipeline at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on Thursday, outlining dosing strategies and market opportunities for its gene therapy programs targeting rare inherited heart conditions.
Shares of Rocket Pharmaceuticals closed at $3.46, down 4.61% from the prior close of $3.63, valuing the company at approximately $381 million. Its stock has traded between $2.53 and $5.45 over the past year.
Chief Executive Officer Gaurav Shah described the company's asset-selection strategy, saying Rocket targets diseases where a clear mechanism of action exists, the protein of interest reaches the right cell, and clinical results can be achieved within a timeframe conducive to regulatory pathways.
The company's three cardiomyopathy programs target Danon disease (LAMP2 deficiency), PKP2-related arrhythmogenic cardiomyopathy, and BAG3-related dilated cardiomyopathy. Shah noted that the recalibrated dose for Danon disease sits at 3.8 E13 vector genomes per kilogram, describing it as landing in what he called the "Goldilocks zone" — the mid-to-low upper E13 range. Earlier Phase 1 data had explored doses in the 4 E13 to 1.1 E14 range, with thrombotic microangiopathy observed only when dosing exceeded 1 E14 vector genomes per kilogram. Shah said the PKP2 dose falls in the same range and declined to specify the BAG3 dosing level while confirming it is similarly positioned.
Shah drew a comparison between gene therapy risk tolerance and oncology treatments, noting that conditioning-related complications such as cytokine release syndrome in CAR T-cell therapies were common yet acceptable given the fatal nature of the diseases and lack of alternatives. He suggested the gene therapy field has been less willing to accept comparable risks.
On commercialization, the Danon disease program benefits from an ICD-10 code that has been in place for 29 months, Shah said. However, he acknowledged that genetic testing coverage remains limited, with only 10% to 20% of U.S. centers currently performing genetic testing for Danon disease.
Market estimates cited by the company indicate at least 15,000 patients with Danon disease in the U.S. and Europe combined, and more than 50,000 patients with PKP2 in the same regions. More than 50 patients have been enrolled in the Danon natural history study.
Separately, Rocket's ex vivo lentiviral portfolio includes KRESLADI, approved for severe Leukocyte Adhesion Deficiency-I, with a commercial launch planned for the fourth quarter of 2024. Additional program updates — including prevalence data and patient identification efforts — are expected in the second half of 2024, with multiple catalysts anticipated over the following nine to twelve months.
The company reported an annual free cash flow burn rate of approximately $170 million, a current ratio of 9.24, and a beta of 0.5. InvestingPro fair value was listed at $4.15 per share.
